{"id":"W2067945145","doi":"10.1016/j.urology.2013.02.077","title":"A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder","year":2013,"lang":"en","type":"article","venue":"Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Mirabegron; Medicine; Overactive bladder; Placebo; Tolerability; Urination; Adverse effect; Randomized controlled trial; Urinary incontinence; Clinical endpoint; Urology; Anesthesia; Internal medicine; Urinary system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008761592,0.0002486042,0.001133369,0.0001504263,0.0001012778,0.00001780302,0.0002341033,0.00009071248,0.0004068039],"category_scores_gemma":[0.0002422125,0.0001172087,0.000109087,0.0002701766,0.0004112219,0.00009406579,0.0001816131,0.0004419843,0.000008223417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003484081,"about_ca_system_score_gemma":0.000119374,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005319444,"about_ca_topic_score_gemma":0.0001522501,"domain_scores_codex":[0.9971492,0.0009520054,0.0006557936,0.000374338,0.0004568908,0.0004118229],"domain_scores_gemma":[0.996829,0.001962601,0.0002747421,0.000491156,0.0003026866,0.0001398506],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9365398,0.007319869,0.04865121,0.00002646485,0.001093019,0.000007140979,0.005102088,0.0001361043,0.00007579115,0.00002965695,0.00007905227,0.0009397829],"study_design_scores_gemma":[0.9256781,0.008009811,0.06402662,0.00002399356,0.0004910446,0.000006239409,0.001029995,0.000475495,0.00005035054,0.00001154683,0.00008194601,0.000114915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795081,0.000175455,0.00008137546,0.001044704,0.00006574481,0.01858005,0.00001509388,0.000009179263,0.0005203017],"genre_scores_gemma":[0.998763,0.00002044785,0.00003875263,0.0002021641,0.00003313845,0.000690906,0.00001811583,0.00002376916,0.0002096722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01925493,"threshold_uncertainty_score":0.4779633,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01888913307314922,"score_gpt":0.3087143719147672,"score_spread":0.289825238841618,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}